Zacks upgraded ResMed (RMD) to a Rank #2 (Buy), indicating increased analyst optimism about the company's earnings prospects. The upgrade could put upward pressure on the stock in the near term and may move the share price by a few percent as investors reposition.
Zacks upgraded ResMed (RMD) to a Rank #2 (Buy), indicating increased analyst optimism about the company's earnings prospects. The upgrade could put upward pressure on the stock in the near term and may move the share price by a few percent as investors reposition.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
